Peak Bio, a biopharmaceutical company, was founded with the mission to develop innovative therapies targeting significant unmet medical needs in oncology and inflammatory diseases. The company focuses on creating treatments for complex conditions, including rare and specialty diseases and cancer. With a robust portfolio of small molecules, antibodies, and antibody-drug conjugates (ADCs), Peak Bio aims to deliver best-in-class therapeutics to improve patient outcomes.
The experienced management team at Peak Bio brings extensive industry expertise, having previously led successful drug development initiatives. The company has garnered attention from notable investors and has achieved key milestones in advancing its therapeutic candidates through various stages of clinical development. Peak Bio's impact is marked by its commitment to addressing critical healthcare challenges and improving the lives of patients with severe and underserved medical conditions.
